BioSpace News Archive

Regor Therapeutics Group today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Thursday, June 12.

Intercept Pharmaceuticals, Inc. today announced new data from a planned six-month analysis of its ongoing Phase 2 study 747-213 evaluating the combination of obeticholic acid (OCA) and bezafibrate in patients with primary biliary cholangitis (PBC) at the European Association for the Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024, in Milan, Italy.

BRIJ Medical, a medical device company revolutionizing surgical incision closure, wound support and scar therapy, is proud to announce the launch of its latest product, the Brijjit BP-75.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding with AstraZeneca during BIO International Convention 2024 to establish a world-class Rare Diseases Centre of Excellence in Abu Dhabi.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme’s ENHANZE® manufacturing methods that the Company provides to its current and future licensees.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 6:20 a.m. PDT / 9:20 a.m. EDT.

Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida, on Wednesday, June 12, 2024.

Can-Fite BioPharma Ltd. today announced an update on the status of its oncological lead drug candidate, Namodenoson in the treatment of advanced liver cancer.

Harrow is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED).

Adicet Bio, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.